SCHEMBL568614

SCHEMBL568614

CCC(=O)Cc1cccc([N+](=O)[O-])c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.56
CYP2D6 P10635 2/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2C19 P33261 2/20 0.52
CYP1A2 P05177 1/20 0.52
ALDH1A1 P00352 4/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
MAOB P27338 2/20 0.50
RECQL P46063 1/20 0.50
SIGMAR1 Q99720 1/20 0.50
MAOA P21397 1/20 0.50
LMNA P02545 1/20 0.50
CES2 O00748 1/20 0.49
CES1 P23141 1/20 0.49
MAPT P10636 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
HPGD P15428 1/20 0.48
ALOX12 P18054 1/20 0.48
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28977512 0.85 ALDH1A1 (0.64) TSHRCYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL2998029 0.84 TSHR (0.65) TSHRALDH1A1SMN1; SMN2MAOBSIGMAR1
SCHEMBL6275759 0.84 TSHR (0.56) TSHRCYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL9644637 0.84 ALDH1A1 (0.50) TSHRCYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL48947 0.83 TSHR (0.59) TSHRCYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL6984479 0.82 KMT2A (0.57) TSHRCYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL2651119 0.81 TSHR (0.61) TSHRCYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL11362791 0.81 TSHR (0.61) TSHRALDH1A1SMN1; SMN2MAOBSIGMAR1
SCHEMBL296300 0.81 TSHR (0.61) TSHRCYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL520733 0.81 MEN1 (0.58) TSHRCYP2D6CYP2C9CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140336208-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2014-11-13 US disclosed
US-8815881-B2 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds HOFFMANN-LA ROCHE INC. (US) 2014-08-26 US disclosed
EP-2603496-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2013-06-19 EP disclosed
CN-103068806-A 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds SIENA BIOTECH SPA 2013-04-24 CN disclosed
WO-2012019966-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2012-02-16 WO disclosed
US-20120035195-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS SIENA BIOTECH S.P.A., AN ITALIAN COMPANY (IT) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336208-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS BACE2, BACE1, PSEN2 TSHR 3173/4885CYP2D6 103/4885CYP2C9 93/4885
US-20120035195-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS BACE2, BACE1, PSEN2 TSHR 3173/4885CYP2D6 103/4885CYP2C9 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.